Lajos Pusztai

Also affiliated with Yale University, Yale New Haven Health System

Biochemistry, Genetics and Molecular BiologyMedicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 1%percentile

5.9Author DataRank

Indexed papers

3in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 3 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapies

Cancer Cell(2022)10.1016/j.ccell.2022.05.005

Top 4%

4.9DataRank

Top 4%329 citations

Christina Yau, Julia Wulfkuhle, Lamorna Brown Swigart, Rosa I. Gallagher, Pei Rong Evelyn Lee +28 more

Papers

Driven by 55 papers — median percentile 78. Top paper: “Association of Event-Free and Distant Recurrence–Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer”.

Association of Event-Free and Distant Recurrence–Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer

JAMA Oncology(2020)10.1001/jamaoncol.2020.2535

N/A

6.3DataRank · unranked

225 citations

Angela DeMichele, Christina Yau, Claudine Isaacs, W. Fraser Symmans, Kathy S. Albain +74 more

Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapies

Cancer Cell(2022)10.1016/j.ccell.2022.05.005

Top 4%

4.9DataRank

Top 4%329 citations

Christina Yau, Julia Wulfkuhle, Lamorna Brown Swigart, Rosa I. Gallagher, Pei Rong Evelyn Lee +28 more

Cisplatin with veliparib or placebo in metastatic triple-negative breast cancer and BRCA mutation-associated breast cancer (S1416): a randomised, double-blind, placebo-controlled, phase 2 trial

The Lancet Oncology(2023)10.1016/s1470-2045(22)00739-2

N/A

2.0DataRank · unranked

102 citations

Priyanka Sharma, William E. Barlow, Julie R. Gralow, Shannon L. Puhalla, Carey K. Anders +16 more

Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients

The Lancet Oncology(2021)10.1016/s1470-2045(21)00589-1

N/A

0.917DataRank · unranked

451 citations

Marie Osdoit, Marieke van der Noordaa, Sonal Shad, Jane Wei, Diane de Croze +94 more

Whole-genome sequencing of phenotypically distinct inflammatory breast cancers reveals similar genomic alterations to non-inflammatory breast cancers

Genome Medicine(2021)10.1186/s13073-021-00879-x

Top 22%

0.914DataRank

Top 22%29 citations

Sushant Kumar, Arif Harmanci, Shantao Li, Robert R. Kitchen, Yan Zhang +11 more

Vitamin D Insufficiency as a Risk Factor for Paclitaxel-Induced Peripheral Neuropathy in SWOG S0221

Journal of the National Comprehensive Cancer Network(2023)10.6004/jnccn.2023.7062

N/A

0.883DataRank · unranked

27 citations

Gary Zirpoli, William E. Barlow, G. Thomas Budd, Bryan McKiver, Lajos Pusztai +10 more

Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial

Cancer Cell(2021)10.1016/j.ccell.2021.05.009

N/A

0.873DataRank · unranked

337 citations

Christina Yau, Denise M. Wolf, Hyo S. Han, Lili Du, Anne M. Wallace +40 more

Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer

npj Breast Cancer(2020)10.1038/s41523-020-0156-0

N/A

0.801DataRank · unranked

208 citations

Elvire Roblin, Rim S. Kim, Stefan Michiels, Brandon D. Gallas, Weijie Chen +95 more

Phase III Randomized, Placebo-Controlled Trial of Endocrine Therapy ± 1 Year of Everolimus in Patients With High-Risk, Hormone Receptor–Positive, Early-Stage Breast Cancer

Journal of Clinical Oncology(2024)10.1200/jco.23.02344

N/A

0.646DataRank · unranked

17 citations

Jieling Miao, Lajos Pusztai, Matthew P. Goetz, Priya Rastogi, Patricia A. Ganz +17 more

Datopotamab–deruxtecan in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial

Nature Medicine(2024)10.1038/s41591-024-03266-2

N/A

0.610DataRank · unranked

13 citations

Jane Meisel, Christina Yau, Hope S. Rugo, Rita Nanda, Marie Davidian +52 more

Thymidine kinase activity levels in serum can identify HR+ metastatic breast cancer patients with a low risk of early progression (SWOG S0226)

Biomarkers(2023)10.1080/1354750x.2023.2168063

N/A

0.587DataRank · unranked

12 citations

Adrian Nordmark, Amy Williams, Costanza Paoletti, William E. Barlow, Erin F. Cobain +11 more

Results of a phase II randomized trial of cisplatin +/- veliparib in metastatic triple-negative breast cancer (TNBC) and/or germline BRCA-associated breast cancer (SWOG S1416).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.1001

N/A

0.587DataRank · unranked

49 citations

Eve T. Rodler, William E. Barlow, Julie R. Gralow, Shannon Leigh Huggins-Puhalla, Carey K. Anders +15 more

Predicted sensitivity to endocrine therapy for stage II-III hormone receptor-positive and HER2-negative (HR+/HER2−) breast cancer before chemo-endocrine therapy

Annals of Oncology(2021)10.1016/j.annonc.2021.02.011

N/A

0.574DataRank · unranked

45 citations

Christina Yau, Lamorna Brown Swigart, Rebekah Gould, Gregor Krings, Gillian L. Hirst +27 more

Ganitumab and metformin plus standard neoadjuvant therapy in stage 2/3 breast cancer

npj Breast Cancer(2021)10.1038/s41523-021-00337-2

N/A

0.510DataRank · unranked

29 citations

Claudine Isaacs, Denise M. Wolf, Christina Yau, Paul Haluska, Karthik V. Giridhar +50 more

Image analysis-based tumor infiltrating lymphocytes measurement predicts breast cancer pathologic complete response in SWOG S0800 neoadjuvant chemotherapy trial

npj Breast Cancer(2023)10.1038/s41523-023-00535-0

N/A

0.498DataRank · unranked

11 citations

Yalai Bai, Vasiliki Pelekanou, Zeina Nahleh, Saba Shafi, Sneha Burela +12 more

Pathologic complete response (pCR) rates for patients with HR+/HER2− high-risk, early-stage breast cancer (EBC) by clinical and molecular features in the phase II I-SPY2 clinical trial

Annals of Oncology(2024)10.1016/j.annonc.2024.10.018

N/A

0.494DataRank · unranked

26 citations

David S. Wolf, Christina Yau, Lamorna Brown Swigart, Gillian L. Hirst, Claudine Isaacs +15 more

Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial—Efficacy and Biomarker Discovery

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-22-2256

N/A

0.457DataRank · unranked

20 citations

Christina Yau, Emanuel F. Petricoin, Denise M. Wolf, Julie E. Lang, A. Jo Chien +44 more

Evaluating Serum Thymidine Kinase 1 in Patients with Hormone Receptor–Positive Metastatic Breast Cancer Receiving First-line Endocrine Therapy in the SWOG S0226 Trial

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-21-1562

N/A

0.457DataRank · unranked

20 citations

William E. Barlow, Erin F. Cobain, Mattias Bergqvist, Rita S. Mehta, Julie R. Gralow +9 more

Diverse immune response of DNA damage repair-deficient tumors

Cell Reports Medicine(2021)10.1016/j.xcrm.2021.100276

N/A

0.449DataRank · unranked

19 citations

Tomi Jun, Katherine E. Lindblad, Amaia Lujambio, Michal Marczyk, Lajos Pusztai +2 more

Race and clinical outcomes in hormone receptor-positive, HER2-negative, node-positive breast cancer in the randomized RxPONDER trial

JNCI Journal of the National Cancer Institute(2024)10.1093/jnci/djae314

N/A

0.443DataRank · unranked

10 citations

William E. Barlow, Julie R. Gralow, Funda Meric‐Bernstam, Kathy S. Albain, Daniel F. Hayes +19 more

Immunological and clinicopathological features predict HER2-positive breast cancer prognosis in the neoadjuvant NeoALTTO and CALGB 40601 randomized trials

Nature Communications(2023)10.1038/s41467-023-42635-2

N/A

0.434DataRank · unranked

17 citations

Aranzazu Fernández-Martínez, David Venet, Françoise Rothé, Katherine A. Hoadley, Joel S. Parker +17 more

Pathologic complete response (pCR) rates for HR+/HER2- breast cancer by molecular subtype in the I-SPY2 Trial.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.504

N/A

0.416DataRank · unranked

15 citations

Hope S. Rugo, Lajos Pusztai, Rita A. Mukhtar, A. Jo Chien, Christina Yau +7 more

GABAA receptor π forms channels that stimulate ERK through a G-protein-dependent pathway

Molecular Cell(2024)10.1016/j.molcel.2024.11.016

N/A

0.345DataRank · unranked

9 citations

Yalan Zhang, Wenxue Li, Barbora Salovska, Jianan Zhang, Tongqing Li +6 more

Multi-platform biomarkers of response to an immune checkpoint inhibitor in the neoadjuvant I-SPY 2 trial for early-stage breast cancer

Cell Reports Medicine(2024)10.1016/j.xcrm.2024.101799

N/A

0.345DataRank · unranked

9 citations

Denise M. Wolf, Christina Yau, Lamorna Brown Swigart, Julie Wulfkuhle, Isela Gallagher +21 more

Cancer-specific associations of driver genes with immunotherapy outcome

bioRxiv (Cold Spring Harbor Laboratory)(2020)10.1101/2020.06.16.155895

N/A

0.208DataRank · unranked

3 citations

Tao Qing, Guanlan Dong, Maxim Signaevski, Julia F. Hopkins, Garrett M. Frampton +7 more

Pre-treatment amino acids and risk of paclitaxel-induced peripheral neuropathy in SWOG S0221

Cancer Chemotherapy and Pharmacology(2024)10.1007/s00280-024-04680-6

N/A

0.104DataRank · unranked

1 citations

Gary Zirpoli, G. Thomas Budd, William E. Barlow, Lajos Pusztai, Gabriel N. Hortobágyi +8 more

Correlation of HER2 low status in I-SPY2 with molecular subtype, response, and survival.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.514

N/A

0.104DataRank · unranked

1 citations

Denise M. Wolf, Christina Yau, Emanuel F. Petricoin, Paula R. Pohlmann, Lajos Pusztai +10 more

Pre-treatment Amino Acids and Risk of Paclitaxel-induced Peripheral Neuropathy in SWOG S0221

Research Square(2023)10.21203/rs.3.rs-3242513/v1

N/A

0.104DataRank · unranked

1 citations

Gary Zirpoli, G. Thomas Budd, William E. Barlow, Lajos Pusztai, Gabriel N. Hortobágyi +8 more

Race and Clinical Outcomes in Hormone Receptor-Positive, HER2-Negative, Node-Positive Breast Cancer in the Randomized RxPONDER Trial

UNC Libraries(2025)10.17615/dgtt-ap31

N/A

0DataRank · unranked

0 citations

Julie R. Gralow, Edith Perez, Kevin Kalinsky, Gabriel N. Hortobágyi, Nancy U. Lin +19 more

Multi-Omics Investigation of Innate Navitoclax Resistance in Triple-Negative Breast Cancer Cells

Cancers(2020)10.3390/cancers12092551

N/A

0DataRank · unranked

20 citations

Gauri A. Patwardhan, Jun Zhao, Rihao Qu, Xiaotong Li, Vikram B. Wali +8 more

Analysis of Pre- and Posttreatment Tissues from the SWOG S0800 Trial Reveals an Effect of Neoadjuvant Chemotherapy on the Breast Cancer Genome

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-19-2405

N/A

0DataRank · unranked

18 citations

Vikram B. Wali, Xiaotong Li, William E. Barlow, Zeina Nahleh, Alastair M. Thompson +4 more

CECR2 Drives Breast Cancer Metastasis by Suppressing Macrophage Inflammatory Responses

bioRxiv (Cold Spring Harbor Laboratory)(2020)10.1101/2020.09.10.291799

N/A

0DataRank · unranked

2 citations

Zongzhi Liu, Keisuke Aoshima, Yangyi Zhang, Yongyan An, Asako Aoshima +14 more

Tumor-Specific Major Histocompatibility-II Expression Predicts Benefit to Anti–PD-1/L1 Therapy in Patients With HER2-Negative Primary Breast Cancer

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-21-0607

N/A

0DataRank · unranked

91 citations

Julia D. Wulfkhule, Rosa I. Gallagher, Xiaopeng Sun, Margaret L. Axelrod, Quanhu Sheng +10 more

Neoadjuvant endocrine therapy use in early stage breast cancer during the covid-19 pandemic

Breast Cancer Research and Treatment(2021)10.1007/s10549-021-06153-3

N/A

0DataRank · unranked

41 citations

Megan E. Gregory, J.G. Bazan, Maryam B. Lustberg, Shoshana M. Rosenberg, Victoria Blinder +6 more

Targeted RNAseq assay incorporating unique molecular identifiers for improved quantification of gene expression signatures and transcribed mutation fraction in fixed tumor samples

BMC Cancer(2021)10.1186/s12885-021-07814-8

N/A

0DataRank · unranked

10 citations

Michal Marczyk, Michael L. Samuels, Alexander J. Trevarton, Jiaxin Qu, Rosanna Lau +8 more

Characterization of the tumor immune microenvironment of triple-negative breast cancer (TNBC) patients who self-identify as African American (AA) or non-African American (NonAA).

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.564

N/A

0DataRank · unranked

0 citations

Michal Marczyk, Tao Qing, Tess A. O’Meara, Vesal Yaghoobi, Vasiliki Pelekanou +9 more

Tumor immune microenvironment of self-identified African American and non-African American triple negative breast cancer

npj Breast Cancer(2022)10.1038/s41523-022-00449-3

N/A

0DataRank · unranked

22 citations

Tao Qing, Tess A. O’Meara, Vesal Yagahoobi, Vasiliki Pelekanou, Yalai Bai +11 more

Treatment Efficacy Score—continuous residual cancer burden-based metric to compare neoadjuvant chemotherapy efficacy between randomized trial arms in breast cancer trials

Annals of Oncology(2022)10.1016/j.annonc.2022.04.072

N/A

0DataRank · unranked

21 citations

Anna Mrukwa, Christina Yau, Denise M. Wolf, Y.-Y. Chen, Ronald Balassanian +26 more

Comprehensive Analysis of Metabolic Isozyme Targets in Cancer

Cancer Research(2022)10.1158/0008-5472.can-21-3983

N/A

0DataRank · unranked

12 citations

Vignesh Gunasekharan, David Casadevall, Tao Qing, Julia Foldi, Raghav Sehgal +12 more

Pitfalls in machine learning‐based assessment of tumor‐infiltrating lymphocytes in breast cancer: A report of the International Immuno‐Oncology Biomarker Working Group on Breast Cancer

The Journal of Pathology(2023)10.1002/path.6155

N/A

0DataRank · unranked

53 citations

Glenn Broeckx, David B. Page, Chowdhury Arif Jahangir, Sara Verbandt, Zuzana Kos +95 more

Spatial analyses of immune cell infiltration in cancer: current methods and future directions: A report of the International Immuno‐Oncology Biomarker Working Group on Breast Cancer

The Journal of Pathology(2023)10.1002/path.6165

N/A

0DataRank · unranked

51 citations

Glenn Broeckx, Chowdhury Arif Jahangir, Sara Verbandt, Rajarsi Gupta, Jeppe Thagaard +95 more

In silico designed mRNA vaccines targeting CA-125 neoantigen in breast and ovarian cancer

Vaccine(2023)10.1016/j.vaccine.2023.02.048

N/A

0DataRank · unranked

29 citations

Wenxue Ma, Caroline H. Johnson, Sajid Khan, MELINDA L. IRWIN, Lajos Pusztai +1 more

Assessment of stained direct cytology smears of breast cancer for whole transcriptome and targeted messenger RNA sequencing

Cancer Cytopathology(2023)10.1002/cncy.22679

N/A

0DataRank · unranked

9 citations

Chunxiao Fu, Rosanna Lau, Lili Du, Alexander J. Trevarton, Bruno V. Sinn +5 more

356P Prognostic value of the residual cancer burden after neoadjuvant chemotherapy for invasive lobular breast cancer: An international pooled cohort study

Annals of Oncology(2023)10.1016/j.annonc.2023.09.535

N/A

0DataRank · unranked

1 citations

Helena Earl, Christina Yau, David Cameron, Jean Abraham, Larry Hayward +15 more

Data from Evaluating Serum Thymidine Kinase 1 in Patients with Hormone Receptor–Positive Metastatic Breast Cancer Receiving First-line Endocrine Therapy in the SWOG S0226 Trial

(2023)10.1158/1078-0432.c.6530384.v1

N/A

0DataRank · unranked

0 citations

William E. Barlow, Erin F. Cobain, Mattias Bergqvist, Rita S. Mehta, Julie R. Gralow +9 more

Data from Evaluating Serum Thymidine Kinase 1 in Patients with Hormone Receptor–Positive Metastatic Breast Cancer Receiving First-line Endocrine Therapy in the SWOG S0226 Trial

(2023)10.1158/1078-0432.c.6530384

N/A

0DataRank · unranked

0 citations

William E. Barlow, Erin F. Cobain, Mattias Bergqvist, Rita S. Mehta, Julie R. Gralow +9 more

Data from An Integrative Genomic and Proteomic Analysis of PIK3CA, PTEN, and AKT Mutations in Breast Cancer

(2023)10.1158/0008-5472.c.6497325

Top 100%

0DataRank

Top 100%0 citations

Ana M. González-Angulo, Aňa Lluch, Richard M. Neve, Wen-lin Kuo, Michael A. Davies +17 more

Comparing the prognostic and predictive utility of serum thymidine kinase 1 and CA 15-3 in patients with hormone receptor positive metastatic breast cancer starting first-line endocrine therapy in SWOG S0226.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.1076

N/A

0DataRank · unranked

0 citations

William E. Barlow, Costanza Paoletti, Mattias Bergqvist, Amy Williams, Hanna Ritzén +11 more

Evaluation of large language models as a diagnostic aid for complex medical cases

Frontiers in Medicine(2024)10.3389/fmed.2024.1380148

N/A

0DataRank · unranked

56 citations

Naing Lin Shan, Anran Li, Alexander T. Pearson, Lajos Pusztai, Frederick M. Howard +1 more

Image‐based multiplex immune profiling of cancer tissues: translational implications. A report of the International Immuno‐oncology Biomarker Working Group on Breast Cancer

The Journal of Pathology(2024)10.1002/path.6238

N/A

0DataRank · unranked

16 citations

David B. Page, Glenn Broeckx, Claudia Aura Gonzalez, Caoimbhe Burke, Clodagh Murphy +95 more

Comparative analysis of Ficoll-Hypaque and CytoLyt techniques for blood removal in breast cancer malignant effusions: effects on RNA quality and sequencing outcomes

Journal of the American Society of Cytopathology(2024)10.1016/j.jasc.2024.11.001

N/A

0DataRank · unranked

2 citations

Kevin Tran, Alexander J. Trevarton, Michal Marczyk, Chunxiao Fu, Lili Du +10 more

Impact of anthracyclines in genomic high-risk, node-negative, HR-positive/HER2-negative breast cancer

Annals of Oncology(2025)10.1016/j.annonc.2025.08.002

N/A

0DataRank · unranked

5 citations

Jincong Q. Freeman, Sri G. Yarlagadda, Aishwarya Atmakuri, Kevin Kalinsky, Lajos Pusztai +5 more

Inhibition of MCL-1 and MEK Overcomes MEK Inhibitor Resistance in Triple-Negative and Inflammatory Breast Cancers

Molecular Cancer Therapeutics(2025)10.1158/1535-7163.mct-24-0593

N/A

0DataRank · unranked

2 citations

Moises Tacam, Alex W. Tan, Mary Kathryn Pitner, LaKesla R. Iles, Xiaoding Hu +16 more

Integration of Gene Expression and Digital Histology to Predict Treatment-Specific Responses in Breast Cancer

medRxiv(2025)10.1101/2025.08.25.25334393

N/A

0DataRank · unranked

0 citations

James M. Dolezal, Hanna M. Hieromnimon, Sara J. Venters, Sara Kochanny, Anran Li +31 more

Acute Toxicity in SWOG 1706, a Randomized Trial Comparing Radiotherapy for Inflammatory Breast Cancer with and without Concurrent Olaparib

International Journal of Radiation Oncology*Biology*Physics(2025)10.1016/j.ijrobp.2025.06.1169

N/A

0DataRank · unranked

0 citations

Allison Meisner, Pavani Chalasani, W. Barlow, Jennifer R. Bellon, N. Lynn Henry +14 more

Lajos Pusztai

Indexed papers

Top data-sharing exemplar

Papers